Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients

Moleculin Biotech reported updated interim data from Part A of its pivotal MIRACLE trial in relapsed or refractory acute myeloid leukemia.

• Results have now been disclosed in a blinded analysis; comprehensive unblinded Part A results are expected in the December 2026 to February 2027 window.
• Patients who previously failed venetoclax showed remission outcomes broadly consistent with the overall study population.
• The company continued to report no signal of cardiac toxicity, supporting its differentiation from standard anthracyclines.
• Enrollment reached 74 of 90 patients; the final Part A treatment is expected in September 2026, a key step toward advancing the program.